Application of ENO1 lactylation related polypeptide Peptide-K71 in treatment of sepsis

By designing and synthesizing a specific polypeptide Peptide-K71 targeting the ENO1 protein, competitively inhibiting the lactic modification of the ENO1-K71 site in sepsis, solving the problems of endothelial dysfunction and increased vascular permeability in sepsis. The survival status and microcirculation function of septic mice were significantly improved.

CN118878643APending Publication Date: 2024-11-01CHILDRENS HOSPITAL OF FUDAN UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411203107.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

The prior art lacks effective treatments to improve endothelial cell dysfunction and increased vascular permeability in sepsis, resulting in microcirculation disorders and multi-organ failure, and fluid resuscitation may lead to fluid overload and aggravate patient outcomes.

Method used

By artificially synthesizing Peptide-K71, a specific polypeptide targeting ENO1 protein, competitively inhibits the lactic modification of the ENO1-K71 site, restores endothelial cell function, reduces vascular permeability, and improves microcirculation disorders in sepsis.

Benefits of technology

Peptide-K71 significantly inhibits the lactic modification of ENO1-K71 site, partially restores endothelial function, reduces vascular damage, improves the survival status and microvascular permeability of septic mice, and avoids the risk of multi-organ failure caused by fluid overload.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005018280090000031
    Figure BDA0005018280090000031
  • Figure FDA0005018280080000011
    Figure FDA0005018280080000011
  • Figure HDA0005018280100000011
    Figure HDA0005018280100000011
Patent Text Reader

Abstract

The invention relates to the field of biological medicines, and discloses an application of ENO1 protein lactylation related polypeptide Peptide-K71 in treatment of sepsis. Cell culture and animal in-vivo experiments show that the lactic acid modification of the ENO1-K71 site causes vascular endothelial dysfunction, and further causes increase of sepsis vascular permeability and damage of microcirculation. According to the present invention, the specific polypeptide-Peptide-K71 for the ENO1-K71 site is chemically synthesized, such that the lactic acid modification of the ENO1-K71 site can be competitively inhibited so as to inhibit the vascular endothelial injury and recover the vascular homeostasis, and the prognosis of the sepsis patient is easily achieved; therefore, a new target is provided for clinical treatment of sepsis vascular injury, meanwhile, a new direction for clinical sepsis treatment is opened up, microcirculation perfusion of sepsis patients is expected to be recovered, and the overall prognosis of the patients is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of biomedicine, and more specifically, to the use of an ENO1 lactylation-related polypeptide Peptide-K71 in the treatment of sepsis. Background Art

[0002] Sepsis is a life-threatening systemic multi-organ dysfunction (Sepsis-3) caused by a dysregulated host response to infection, which is common in complications such as severe infection, trauma, burns, shock and major surgical operations. With the rapid progression of sepsis severity, it can develop into severe sepsis and septic shock, with an average mortality rate of 25%-30% for patients with sepsis and 40%-50% for patients with septic shock. The latest Global Burden of Disease study shows that there were 48.9 million cases of sepsis and 11 million deaths worldwide in 2017. The pathogenesis of sepsis is still unclear. According to the "International Guidelines for the Management of Sepsis and Septic Shock", there is currently no specific and effective treatment in clinical practice except for fluid resuscitation, antibiotics and organ support. Endothelial cells are an important single-layer barrier of blood vessels, and changes in their homeostasis are the main factor causing organ dysfunction in sepsis and inflammatory critical illnesses. During sepsis, the engagement of pattern recognition receptors (PRRs) drives endothelial cells to reprogram toward pro-inflammatory, pro-apoptotic, pro-adhesive, and pro-coagulant phenotypes; in addition, endothelial glycocalyx damage, microcirculatory vascular reactivity disorders, capillary leakage, and impaired tissue perfusion in sepsis will further aggravate patient symptoms. A large amount of clinical evidence shows that patients with sepsis often experience progressive tissue and body cavity edema, indicating increased vascular permeability. The goal of fluid resuscitation in management guidelines is to protect endothelial cells while maintaining microcirculatory perfusion, with the ultimate goal of alleviating organ failure and improving sepsis outcomes. However, in some cases, fluid resuscitation may lead to fluid overload, further aggravating subsequent multi-organ failure and worsening the prognosis of patients with sepsis. Therefore, treatments aimed at improving vascular homeostasis and restoring endothelial function can provide another approach to treating sepsis.

[0003] Lactate is the main byproduct of glycolysis. In clinical sepsis patients, increased lactate (caused by hypoxia and mitochondrial dysfunction) and reduced clearance (caused by kidney and liver damage) further lead to elevated lactate levels, so high levels of serum lactate have been considered a key biomarker for sepsis prognosis. Recent studies have shown that lactate is not only a biomarker, but also an effective signaling molecule that can regulate immune responses during sepsis. Lactylation modification is a new type of protein post-translational modification (PTM) discovered in 2019. It exists in both histones and non-histone proteins, and more and more studies have revealed that lactylation modification plays an important role in regulating homologous recombination repair, immunosuppression, metabolic transformation and other aspects. At present, the mechanism of lactylation modification is still unclear, and the key proteins and key sites of lactylation in the body are different in different disease states. Therefore, there is no effective and specific treatment to change the body's lactic acid state and alleviate the related disease phenotypes. In the high-lactate environment of sepsis, lactic acid modification of related proteins also exists, which may play an important role in the progression of sepsis.

[0004] Peptide drugs refer to peptides with specific therapeutic effects extracted through chemical synthesis (chemical pharmaceuticals), genetic recombination (biopharmaceuticals) or animals and plants. They are molecules between small molecules and macromolecules and are the specific application of peptides in the field of medicine. Peptides occupy a unique position in the field of drug research and development. Since the advent of therapeutic insulin in 1922, peptide therapy has played an important role in medical practice. In recent years, with the development and maturity of peptide synthesis technology, peptide drugs have been widely used in the prevention, diagnosis and treatment of diseases such as tumors, cardiovascular and cerebrovascular diseases, hepatitis, and diabetes due to their wide indications, high safety, and significant efficacy. They have broad development prospects. Therefore, peptide therapy is currently considered to be a potential therapy with high selectivity, effectiveness, and relative safety. Although peptides have the advantages of high specificity, good efficacy, and low accumulation, they are more suitable for long-term administration, but their administration route is mostly intravenous injection. Due to the presence of amide bonds that are sensitive to biological enzymes, the C-terminus / N-terminus of the residues, and easy oxidation and racemization, peptides have poor chemical stability. Even after injection, they are still easily affected by factors such as enzymes in the blood, blood flow shear force, and enzymes in the tissues and are degraded. Therefore, the structural optimization of peptides is the most commonly used and mature strategy for their development. To date, the research on oral peptides has become increasingly in-depth, from the relationship between peptide chemical bond sensitivity and gastrointestinal enzymes, the relationship between spatial structure and transmembrane absorption, to the promotion effect of different excipients or formulation technologies on their oral absorption. The research on various aspects of peptides has continued to deepen, and new excipients and new technologies have continued to pour in. Among the peptide drugs entering clinical or preclinical research, research on inhalation administration, microneedle delivery, and nano-delivery systems has also become increasingly mature. With the emergence of new materials and new formulation technologies, peptides will still be one of the research hotspots in biomedicine. In recent years, with the discovery of a variety of protein post-translational modifications in various basic research, artificial synthesis of specific peptides has gradually become one of the strategies for protein post-translational modification intervention, such as competitive inhibition of phosphorylation, glycosylation, ubiquitination, lactylation, etc., which have affected the occurrence of target protein-related post-translational modifications to a certain extent.

[0005] Therefore, it is of great significance to provide a peptide treatment strategy for the treatment of sepsis. Summary of the invention

[0006] The purpose of the present invention is to provide a polypeptide treatment strategy for the treatment of sepsis - targeting the lactic acidization of the ENO1-K71 site of endothelial cells, artificially synthesizing transmembrane polypeptides of related modified sites, and improving endothelial damage in sepsis.

[0007] In order to achieve the above-mentioned purpose, the present invention provides a specific polypeptide Peptide-K71 related to lactic acidation of ENO1 protein and its application in the preparation of a drug for treating sepsis. In the process of sepsis, Peptide-K71 can competitively inhibit the lactic acid modification of ENO1-K71 site, alleviate the microcirculatory disorder of sepsis, and improve the survival status.

[0008] In the first aspect, the present application provides a specific polypeptide Peptide-K71, whose molecular formula is C 174 H 283 O 41 N 57 S, the structural formula is shown in the following formula (1):

[0009]

[0010] In a second aspect, the present application provides use of the specific polypeptide Peptide-K71 in the first aspect in the preparation of a drug for treating vascular endothelial injury caused by sepsis.

[0011] Preferably, the specific polypeptide Peptide-K71 can alleviate the microcirculatory disorder of sepsis, and the improvement of survival status is achieved by protecting endothelial cells and restoring vascular homeostasis.

[0012] In a third aspect, the present application provides the use of ENO1-K71 as a target in the preparation of a drug for treating vascular endothelial injury in sepsis.

[0013] The present invention also provides a specific molecular mechanism by which ENO1-K71 site lactic acid modification damages vascular endothelial cells, including that ENO1-K71 site lactic acid modification ubiquitin-degrades endothelial tight junction protein VE-cadherin, thereby damaging endothelial function.

[0014] Preferably, the increased lactylation modification level of the ENO1-K71 site is detected by 4D protein lactylation mass spectrometry.

[0015] Preferably, the vascular endothelial function damage includes degradation of endothelial tight junction proteins, slowed proliferation, and increased permeability.

[0016] Among them, the specific polypeptide Peptide-K71 can competitively inhibit the lactic acid modification of the ENO1-K71 site, thereby protecting the endothelial function. Therefore, in the fourth aspect, the present application provides the use of a substance that inhibits the lactic acid modification of the ENO1-K71 site in the preparation of a drug for treating vascular endothelial damage in sepsis.

[0017] In a fifth aspect, the present application provides a drug comprising the specific polypeptide Peptide-K71 described in the first aspect, wherein the drug is used to treat vascular endothelial injury caused by sepsis.

[0018] The present invention finds that the body's lactic acid level increases in sepsis, and the ENO1-K71 site in vascular endothelial cells undergoes obvious lactic acid modification, resulting in impaired vascular endothelial function and increased vascular permeability. Reducing the lactic acid modification of this site can partially restore endothelial function. By chemically synthesizing ENO1-K71 site-related polypeptides and optimizing their structures, it is found that they can significantly competitively inhibit the lactic acid modification of the ENO1-K71 site, thereby restoring vascular permeability and improving sepsis microcirculation disorders.

[0019] Different from previous studies, this study discovered for the first time that lactic acid modification of the K71 site of the ENO1 protein in vascular endothelial cells can ubiquitinate and degrade the vascular endothelial-specific tight junction protein VE-cadherin through related pathways, leading to endothelial damage and increased vascular permeability. By inhibiting lactic acid modification of the ENO1-K71 site in endothelial cells, endothelial damage can be alleviated and microcirculatory disorders caused by increased vascular permeability in sepsis can be partially restored. Unlike previous studies that focused on some small molecule inhibitors, this study designed and chemically synthesized a specific peptide targeting the ENO1-K71 site, Peptide-K71, for the first time, proving that it can effectively inhibit lactic acid modification of the ENO1-K71 site and improve endothelial function.

[0020] Compared with the prior art, the present invention has the following beneficial effects:

[0021] The present invention uses 4D protein lactylation mass spectrometry to detect that the ENO1-K71 site in the vascular endothelium of sepsis is significantly lactated, and inhibiting this modification can restore endothelial function and reduce vascular damage. Once lactation occurs, the modification of the relevant site will persist. Therefore, when the lactate clearance strategy is adopted clinically, the lactation modification of vascular endothelial-related proteins such as ENO1 cannot be cleared, which will lead to continuous damage to the vascular endothelium. In addition, in some cases, fluid resuscitation in the management guidelines may lead to fluid overload, further aggravating the subsequent multiple organ failure and the worsening prognosis of sepsis patients. The peptide-K71 polypeptide treatment strategy in the present invention can inhibit the occurrence of lactation of the ENO1-K71 site from the root, thereby improving sepsis vascular dysfunction. In addition, polypeptide therapy has not yet been studied in the field of sepsis, and Peptide-K71 may provide a therapeutic strategy for future interventions in the field of post-translational modification of key proteins in sepsis. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1The results showed that the blood vessels of septic mice underwent obvious lactic acid modification, which led to increased vascular permeability. A. Changes in serum lactate levels in mice after CLP modeling; B. WB detection of lactic acid changes in mouse vascular tissue; C. Immunofluorescence detection of lactic acid changes in mouse vascular tissue (CD31: purple; PanKla: green; DAPI: blue); D. Evans Blue detection of microvascular permeability in the liver, lung, and kidney of mice; E. Changes in serum lactate levels in mice after the action of LDHA inhibitor; F. WB detection of lactic acid changes in mouse vascular tissue after the action of LDHA inhibitor; G. Evans Blue detection of microvascular permeability in the liver, lung, and kidney of mice after the action of LDHA inhibitor (ns=no significance, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).

[0023] Figure 2 The results show that lactic acid modification of ENO1-K71 site in vascular endothelial cells impairs endothelial function. A. IP-MS detection of lactic acid modified proteins in endothelial cells; B. KEGG enrichment analysis of related pathways after RNA-seq detection; C. IP-WB detection of lactic acid modification of ENO1 in vascular endothelial cells; D. Mass spectrum peak of lactic acid modification of ENO1-K71 site; E. Protein structure diagram of ENO1-K71 site; F. IP-WB detection of lactic acid modification of ENO1-K71 site.

[0024] Figure 3 The specific peptide Peptide-K71 plays an important role in restoring endothelial homeostasis and reducing vascular permeability in sepsis. A. Flow cytometry was used to detect the optimal concentration of Peptide-K71 entering cells; B. Flow cytometry was used to detect the half-life of Peptide-K71 in endothelial cells; C. WB was used to detect the effect of Peptide-K71 on the lactic acidification of the ENO1-K71 site in endothelial cells; D. Transwell was used to detect the permeability of endothelial cells after the action of Peptide-K71; E. CCK8 was used to detect the proliferation of endothelial cells after the action of Peptide-K71; F. Schematic diagram of septic mice injected with Peptide-K71 in vitro; G. Survival of septic mice after modeling and administration; H. Evans Blue was used to detect the microvascular permeability of the liver, lung, and kidney of mice after the action of LDHA inhibitor; I. ​​Changes in LDH, AST, and CK in mouse serum were detected (ns=no significance, **p<0.01, ***p<0.001).

[0025] Figure 4 The structural formula of the specific peptide Peptide-K71 is shown. DETAILED DESCRIPTION

[0026] In order to make the present invention more clearly understood, preferred embodiments are described in detail below with reference to the accompanying drawings.

[0027] In the following examples, the experimental methods used are conventional methods unless otherwise specified; the materials, reagents, etc. used are conventional commercially available products unless otherwise specified; the quantitative tests involved are set up with three repeated experiments, and the results are averaged.

[0028] In the following examples, some experimental materials and methods include:

[0029] 1. Establishment of Cecal Ligation and Puncture (CLP) Sepsis Mouse Model

[0030] Mice were anesthetized by intraperitoneal injection of 200 μL 1.25% Avertin. The skin was disinfected and prepared, and the skin and peritoneum were cut layer by layer in the lower abdominal area of ​​the mouse to expose the mouse abdominal cavity. The cecum was freed, and the lower half of the cecum was ligated. A 20G needle was used to pierce the end of the ligated cecum once, and a small amount of contents was squeezed out. The cecum was returned to the abdominal cavity, and the peritoneum and skin were sutured layer by layer with sutures. After surgery, the mice were subcutaneously injected with 1 mL of normal saline and placed on a 37°C warm pad for resuscitation. The sham-operated mice were operated in the same manner except that the cecum was not ligated and punctured.

[0031] 2. Western blot

[0032] RIPA lysis buffer (Thermo) and Protease inhibitor (Thermo) were used to lyse cells at a ratio of 100:1, and total protein was fully lysed and extracted on ice using an ultrasonic cell disruptor (BioX). Antibodies ENO1 (Abcam), VE-cadherin (CST), β-tubilin (Abam), and PanKla (Jingjie Biotechnology).

[0033] 3. Vascular Permeability Detection in Sepsis Mice

[0034] Mice with sepsis were injected with 150 μL of 0.5% Evans Blue through the tail vein. Mice were killed by dislocation of the neck 30 minutes later and the liver, lung and kidney, about 50-200 mg each, were taken out. After washing and weighing, 500 μL of formamide was added and the mixture was extracted in a 55°C oven for 48 hours. The supernatant was then centrifuged and the absorbance at 610 nm was detected. The relative exudation of Evans Blue per milligram of tissue was calculated, thereby reflecting the changes in microvascular permeability.

[0035] 4.4D protein lactylation modification mass spectrometry detection

[0036] The vascular endothelial cell proteins stimulated by lipopolysaccharide (LPS) and LAC were subjected to SDS-PAGE gel electrophoresis, and the gel strips were stained with Coomassie Brilliant Blue for 2 hours and repeatedly washed with ddH2O until the gel strip background was transparent. After gel cutting, enzymatic hydrolysis, peptide extraction, and desalting, the gel strips were subjected to lactate mass spectrometry to detect the abundance and lactate modification of related proteins.

[0037] 5. Chemical synthesis of peptide-K71

[0038] Based on the amino acid sequence near the ENO1-K71 site and the peptide sequence detected by IP-MS, the target peptide sequence to be synthesized was determined; and based on the company's suggestions, a suitable transmembrane peptide was added to the front of the target sequence to improve the efficiency of cell entry; at the same time, a FITC group was added at the appropriate position to detect whether the synthetic peptide had entered the cell and exerted its effect through fluorescence intensity; and the stability of the synthetic peptide in the cell was improved by introducing some specific amino acids.

[0039] 6. Peptide-K71 treatment of septic mice

[0040] Peptide-K71 was injected into the tail vein four times at a dose of 3 mg / kg at 6 h, d 1, d 2, and d 3 after CLP. The control group was injected with the same volume of saline.

[0041] Example 1: Vascular lactic acidification in septic mice leads to increased vascular permeability

[0042] The results of serum lactate detection showed that the serum lactate level of septic mice after CLP modeling was significantly increased ( Figure 1 A); Western Blot analysis of the isolated inferior vena cava revealed that the lactic acid modification level of vascular tissue in septic mice was significantly increased, while the expression of vascular-specific tight junction protein VE-cadherin was decreased ( Figure 1 B), indicating that vascular tight junctions were damaged; immunofluorescence further verified that the lactic acid level of vascular tissue in septic mice was increased ( Figure 1 C). Evans Blue experiments have shown that the permeability of microvessels in the lungs, livers, and kidneys of septic mice increases ( Figure 1 D), indicating that septic mice had vascular dysfunction, which in turn caused microcirculation damage. When septic mice were given lactate dehydrogenase inhibitors (LDHAi), the serum lactate level of the mice decreased ( Figure 1 E), while the lactic acid level of vascular tissue was also reduced, and VE-cadherin expression was partially restored ( Figure 1 F), the microvascular permeability of the lungs, liver, and kidneys of mice also decreased to a certain extent ( Figure 1G), indicating that inhibiting lactate production in septic mice can reduce vascular tissue lactic acidification and thus reduce vascular permeability.

[0043] The above results indicate that vascular endothelial lactic acidification caused by elevated lactate levels can lead to increased vascular permeability and disruption of vascular homeostasis.

[0044] Example 2: Lactic acid modification of ENO1-K71 site in vascular endothelial cells impairs endothelial function

[0045] The vascular endothelial cell proteins after sepsis simulation stimulation (LPS+LAC) were subjected to 4D protein lactylation mass spectrometry detection, and it was found that the lactic acid modification level of intracellular proteins was significantly increased ( Figure 2 A). Combining the enrichment analysis of KEGG and GO related pathways, it was found that the lactic acid differentially expressed proteins were mainly enriched in glycolysis and mRNA stability regulation related pathways ( Figure 2 B). As a key enzyme involved in the glycolysis process, ENO1 can not only affect the glycolysis process and lactate production, but also regulate the stability of mRNA as an RNA binding protein. Immunoprecipitation further verified that after LPS+LAC sepsis simulation stimulation, ENO1 underwent obvious lactic acid modification ( Figure 2 C). The mass spectrometry peak diagram shows that the lactic acid modification level of ENO1-K71 site is the highest ( Figure 2 D), and lactylation modification may affect the structure near the K71 site ( Figure 2 E). To further verify whether the ENO1-K71 site is a key site for ENO1 lactylation, we constructed a normal plasmid (Flag-ENO1-WT) and a mutant plasmid (Flag-ENO1-K71R) for this site. Overexpression of these two plasmids in ENO1-KO endothelial cells revealed that the lactylation of ENO1 was significantly inhibited after the K71 site mutation ( Figure 2 F), suggesting that K71 is a key site affecting ENO1 lactylation modification, and lactylation modification of this site can cause vascular endothelial dysfunction.

[0046] The above results indicate that lactylation modification of the ENO1-K71 site in the vascular endothelium of sepsis is an important factor affecting endothelial function and homeostasis.

[0047] Example 3: Specific peptide Peptide-K71 restores endothelial homeostasis in sepsis and reduces vascular permeability

[0048] Since there is currently no effective means to construct gene-edited mice that simulate lactylation modification sites, combined with previous studies, artificially synthesized peptides may be able to specifically affect the post-translational modification of related proteins in vivo. In order to further verify that inhibiting lactylation at the ENO1-K71 site can improve endothelial function, we considered designing and artificially synthesizing specific peptides for the ENO1-K71 site to competitively inhibit lactylation modification at the ENO1-K71 site in vivo. According to the amino acid sequence near the ENO1-K71 site and the peptide sequence detected by IP-MS, the target peptide sequence to be synthesized was determined; and combined with the company's suggestions, a suitable transmembrane peptide was added to the front of the target sequence to improve the efficiency of cell entry; at the same time, a FITC group was added at the appropriate position to detect whether the synthetic peptide has entered the cell and played a role through fluorescence intensity; the stability of the synthetic peptide in the cell was improved by introducing some specific amino acids; based on the above, the target peptide Peptide-K71 was designed. First, the cell entry efficiency and half-life of the peptide were verified in endothelial cells cultured in vitro by flow cytometry ( Figure 3 A, 3B). Immunoprecipitation experiments showed that Peptide-K71 could significantly inhibit the lactylation of ENO1 ( Figure 3 C), and can reduce the permeability of vascular endothelial cells to a certain extent ( Figure 3 D), increase the proliferation of endothelial cells ( Figure 3 E), partially restoring the function of endothelial cells. We then further verified in septic mice whether Peptide-K71 could play the same role as in vitro cells. After septic mice were modeled, Peptide-K71 was injected into the tail vein ( Figure 3 F), can effectively improve the survival rate of septic mice ( Figure 3 G), the microvascular permeability of the lungs, liver, and kidneys also decreased to a certain extent ( Figure 3 H), and the indicators of multiple organ failure in mice were also alleviated ( Figure 3 I).

[0049] The above results indicate that the ENO1-specific peptide Peptide-K71 can inhibit the lactation of the ENO1-K71 site in the vascular endothelium of septic mice, thereby improving the vascular homeostasis and survival of septic mice.

[0050] The above description is only a preferred embodiment of the present invention and is not any formal or substantial limitation of the present invention. It should be pointed out that a person skilled in the art can make several improvements and supplements without departing from the present invention, and these improvements and supplements should also be regarded as the protection scope of the present invention.

Claims

1. A specific polypeptide Peptide-K71, characterized in that: Its molecular formula is C 174 H 283 O 41 N 57 S, the structural formula is shown in the following formula (1):

2. Use of the specific polypeptide Peptide-K71 according to claim 1 in the preparation of a drug for treating vascular endothelial damage caused by sepsis.

3. Application of ENO1-K71 as a target in the preparation of drugs for the treatment of vascular endothelial damage in sepsis.

4. Use of substances that inhibit lactic acid modification of the ENO1-K71 site in the preparation of drugs for treating vascular endothelial damage in sepsis.

5. A drug, characterized in that It comprises the specific polypeptide Peptide-K71 as claimed in claim 1.

Citation Information

Cited By

  • Application of preparation for preventing ENO1 from playing glycolysis effect in preparation of medicine for treating sepsis

    CN120204405A